Analyst Ratings for Cullinan Oncology
Portfolio Pulse from Benzinga Insights
In the last quarter, Cullinan Oncology (NASDAQ:CGEM) received 5 bullish analyst ratings. The company has an average 12-month price target of $49.0, representing a 2.0% decrease from the previous average price target of $50.00.
August 09, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cullinan Oncology received 5 bullish analyst ratings in the last quarter, with an average 12-month price target of $49.0.
The bullish analyst ratings indicate a positive outlook for Cullinan Oncology. However, the decrease in the average price target could potentially indicate a slight decrease in the expected stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100